1. Home
  2. BMRN vs CACI Comparison

BMRN vs CACI Comparison

Compare BMRN & CACI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BMRN
  • CACI
  • Stock Information
  • Founded
  • BMRN 1996
  • CACI 1962
  • Country
  • BMRN United States
  • CACI United States
  • Employees
  • BMRN N/A
  • CACI N/A
  • Industry
  • BMRN Biotechnology: Pharmaceutical Preparations
  • CACI EDP Services
  • Sector
  • BMRN Health Care
  • CACI Technology
  • Exchange
  • BMRN Nasdaq
  • CACI Nasdaq
  • Market Cap
  • BMRN 9.9B
  • CACI 11.7B
  • IPO Year
  • BMRN 1999
  • CACI 1979
  • Fundamental
  • Price
  • BMRN $55.07
  • CACI $588.66
  • Analyst Decision
  • BMRN Buy
  • CACI Strong Buy
  • Analyst Count
  • BMRN 19
  • CACI 13
  • Target Price
  • BMRN $90.26
  • CACI $601.91
  • AVG Volume (30 Days)
  • BMRN 2.8M
  • CACI 270.1K
  • Earning Date
  • BMRN 10-27-2025
  • CACI 10-22-2025
  • Dividend Yield
  • BMRN N/A
  • CACI N/A
  • EPS Growth
  • BMRN 59.53
  • CACI 12.06
  • EPS
  • BMRN 2.68
  • CACI 22.62
  • Revenue
  • BMRN $3,094,001,000.00
  • CACI $8,858,558,000.00
  • Revenue This Year
  • BMRN $13.32
  • CACI $10.71
  • Revenue Next Year
  • BMRN $7.51
  • CACI $5.73
  • P/E Ratio
  • BMRN $20.49
  • CACI $25.93
  • Revenue Growth
  • BMRN 12.39
  • CACI 12.61
  • 52 Week Low
  • BMRN $50.76
  • CACI $318.60
  • 52 Week High
  • BMRN $73.51
  • CACI $599.78
  • Technical
  • Relative Strength Index (RSI)
  • BMRN 57.93
  • CACI 65.95
  • Support Level
  • BMRN $50.76
  • CACI $573.19
  • Resistance Level
  • BMRN $53.49
  • CACI $599.78
  • Average True Range (ATR)
  • BMRN 1.87
  • CACI 16.22
  • MACD
  • BMRN 0.29
  • CACI 0.24
  • Stochastic Oscillator
  • BMRN 72.52
  • CACI 74.32

About BMRN BioMarin Pharmaceutical Inc.

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.

About CACI CACI International Inc.

CACI International Inc is an information solutions and services provider, offering information solutions and services to its customers. The company's primary customers are agencies and departments of the U.S. government, which account for the vast majority of the firm's revenue. It provides information solutions and services supporting national security missions and government modernization for intelligence, defense, and federal civilian customers. Some of the services provided by the company are functional software development, data, and business analysis, IT operations support, naval architecture, and life cycle support intelligence among others. The company's operating segments are; Domestic operations and International operations. It derives key revenue from the Domestic segment.

Share on Social Networks: